HYPR

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 2

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,557

F3 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Dr. Rothberg's continued service through the applicable vesting date.

SEC source: 0001104659-21-153331 · tm2135698-14_4seq1.xml · nonDerivative · entry 1

Sainz Maria · CIK 0001437768 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,483

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Ms. Sainz's continued service through the applicable vesting date.

SEC source: 0001104659-21-153334 · tm2135698-18_4seq1.xml · nonDerivative · entry 2

Fattori Ruth A · CIK 0001306826 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,374

F3 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Ms. Fattori's continued service through the applicable vesting date.

SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · nonDerivative · entry 1

Huennekens R Scott · CIK 0001365493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,483

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Huennekens' continued service through the applicable vesting date.

SEC source: 0001104659-21-153330 · tm2135698-13_4seq1.xml · nonDerivative · entry 1

Dahldorf John T · CIK 0001365494 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,483

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Dahldorf's continued service through the applicable vesting date.

SEC source: 0001104659-21-153335 · tm2135698-17_4seq1.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,483

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 2

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,660

F3 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Dr. Rothberg's continued service through the applicable vesting date.

SEC source: 0001104659-22-002886 · tm222483-1_4aseq1.xml · nonDerivative · entry 1

Sainz Maria · CIK 0001437768 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,586

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Ms. Sainz's continued service through the applicable vesting date.

SEC source: 0001104659-22-002888 · tm222483-3_4aseq1.xml · nonDerivative · entry 2

Fattori Ruth A · CIK 0001306826 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,477

F3 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Ms. Fattori's continued service through the applicable vesting date.

SEC source: 0001104659-22-002889 · tm222483-4_4aseq1.xml · nonDerivative · entry 1

Huennekens R Scott · CIK 0001365493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,586

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Huennekens' continued service through the applicable vesting date.

SEC source: 0001104659-22-002887 · tm222483-2_4aseq1.xml · nonDerivative · entry 1

Dahldorf John T · CIK 0001365494 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,586

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Dahldorf's continued service through the applicable vesting date.

SEC source: 0001104659-22-002891 · tm222483-6_4aseq1.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,586

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · derivative · entry 8

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 982,500

Underlying: Class A Common Stock · 982,500 shares

Expires 2031-04-14

F11 · price: Received in connection with the Mergers in exchange for a stock option to acquire 3,000,000 shares of Hyperfine common stock for $1.07 per share.

F10 · derivative.exercise_date: The shares underlying this option vested and became exercisable on December 15, 2021.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 7

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By 4C Holdings V, LLC

Disclosed balance after: 818,750

F9 · price: Received in connection with the Mergers in exchange for 2,500,000 shares of Hyperfine Series A preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 6

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By 4C Holdings I, LLC

Disclosed balance after: 14,236,538

F8 · price: Received in connection with the Mergers in exchange for 22,500,000 shares of Hyperfine Series B preferred stock and 38,239,355 shares of Liminal Series A-1 preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 5

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Bonnie E Gould Rothberg MD

Disclosed balance after: 95,507

F7 · price: Received in connection with the Mergers in exchange for 291,625 shares of Hyperfine Series B preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 4

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · 23rd Century Capital LLC

Disclosed balance after: 440,295

F6 · price: Received in connection with the Mergers in exchange for 1,344,413 shares of Hyperfine Series B preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 3

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · 2012 JMR Trust Common, LLC

Disclosed balance after: 585,737

F4 · price: Received in connection with the Mergers in exchange for 1,403,701 shares of Hyperfine Series B preferred stock and 701,700 shares of Liminal Series A-2 preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-21-153337 · tm2135698-20_4seq1.xml · nonDerivative · entry 1

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,074

F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc.,

F2 · price: a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 275,700 shares of Hyperfine Series B preferred stock and 76,739 shares of Liminal Series A-2 preferred stock.

SEC source: 0001104659-21-153336 · tm2135698-19_4seq1.xml · derivative · entry 3

Scott David D · CIK 0001899784 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,875

Underlying: Class A Common Stock · 474,875 shares

Expires 2031-04-27

F8 · price: Received in connection with the Mergers in exchange for a stock option to acquire 1,450,000 shares of Hyperfine common stock for $1.07 per share.

F7 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Scott's start date and the Issuer's common stock achieving a price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Scott's start date and the Issuer's common stock achieving a price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Scott's start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted).

SEC source: 0001104659-21-153336 · tm2135698-19_4seq1.xml · derivative · entry 2

Scott David D · CIK 0001899784 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,875

Underlying: Class A Common Stock · 474,875 shares

Expires 2031-04-27

F6 · price: Received in connection with the Mergers in exchange for a stock option to acquire 1,450,000 shares of Hyperfine common stock for $1.07 per share.

F4 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Scott's start date and the common stock of the Issuer achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within two years of the closing of the SPAC transaction;

F5 · derivative.exercise_date: (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO") within two years of Mr. Scott's start date and the common stock of the Issuer achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within two years of the closing of the IPO; or (3) the closing of a private financing round within two years of Mr. Scott's start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 1.5 times $3.92 (as adjusted).

SEC source: 0001104659-21-153336 · tm2135698-19_4seq1.xml · derivative · entry 1

Scott David D · CIK 0001899784 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,899,500

Underlying: Class A Common Stock · 1,899,500 shares

Expires 2031-04-27

F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"),

F3 · price: with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), this stock option was received in exchange for a stock option to acquire 5,800,000 shares of Hyperfine common stock for $1.07 per share.

F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on June 30, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Scott's continued service through the applicable vesting date.

SEC source: 0001104659-21-153338 · tm2135698d21_4seq1.xml · derivative · entry 4

Siddiqui Khan · CIK 0001898560 · CMO and Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,796

Underlying: Class A Common Stock · 1,796 shares

Expires 2031-05-12

F9 · price: The shares underlying this option vest in forty eight equal monthly installments beginning on October 31, 2020, subject to Dr. Siddiqui's continued service through the applicable vesting date.

F8 · derivative.exercise_date: Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Liminal common stock for $0.94 per share.

SEC source: 0001104659-21-153338 · tm2135698d21_4seq1.xml · derivative · entry 3

Siddiqui Khan · CIK 0001898560 · CMO and Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,037

Underlying: Class A Common Stock · 54,037 shares

Expires 2031-04-14

F7 · price: The shares underlying this option vest in forty eight equal monthly installments beginning on January 31, 2021, subject to Dr. Siddiqui's continued service through the applicable vesting date.

F6 · derivative.exercise_date: Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share.

SEC source: 0001104659-21-153338 · tm2135698d21_4seq1.xml · derivative · entry 2

Siddiqui Khan · CIK 0001898560 · CMO and Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,345

Underlying: Class A Common Stock · 130,345 shares

Expires 2030-01-27

F5 · price: The shares underlying this option vested as to 25% on December 31, 2020, with the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr. Siddiqui's continued service on each vesting date.

F4 · derivative.exercise_date: Received in connection with the Mergers in exchange for a stock option to acquire 398,000 shares of Hyperfine common stock for $1.23 per share.

SEC source: 0001104659-21-153338 · tm2135698d21_4seq1.xml · derivative · entry 1

Siddiqui Khan · CIK 0001898560 · CMO and Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,800

Underlying: Class A Common Stock · 104,800 shares

Expires 2030-01-27

F3 · price: The shares underlying this option vested as to 25% on December 31, 2020, with the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr. Siddiqui's continued service on each vesting date.

F1 · derivative.exercise_date: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal

F2 · derivative.exercise_date: (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in connection with the Mergers in exchange for a stock option to acquire 320,000 shares of Hyperfine common stock for $1.23 per share.

SEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 6

Hughes Mark A. · CIK 0001898765 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,587

Underlying: Class A Common Stock · 60,587 shares

Expires 2031-04-14

F12 · price: Received in connection with the Mergers in exchange for a stock option to acquire 185,000 shares of Hyperfine common stock for $1.07 per share.

F11 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date.

SEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 5

Hughes Mark A. · CIK 0001898765 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,912

Underlying: Class A Common Stock · 4,912 shares

Expires 2031-04-14

F10 · price: Received in connection with the Mergers in exchange for a stock option to acquire 15,000 shares of Hyperfine common stock for $1.07 per share.

F9 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date.

SEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 4

Hughes Mark A. · CIK 0001898765 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,275

Underlying: Class A Common Stock · 3,275 shares

Expires 2030-01-18

F8 · price: Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Hyperfine common stock for $1.23 per share.

F7 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.

SEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 3

Hughes Mark A. · CIK 0001898765 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,037

Underlying: Class A Common Stock · 54,037 shares

Expires 2030-01-18

F6 · price: Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share.

F5 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.

SEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 2

Hughes Mark A. · CIK 0001898765 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,322

Underlying: Class A Common Stock · 21,322 shares

Expires 2029-07-01

F4 · price: Received in connection with the Mergers in exchange for a stock option to acquire 65,106 shares of Hyperfine common stock for $1.23 per share.

F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on September 30, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.

SEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · nonDerivative · entry 1

Hughes Mark A. · CIK 0001898765 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,615

F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc.,

F2 · price: a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 59,894 shares of Hyperfine common stock.

SEC source: 0001104659-21-153333 · tm2135698-16_4seq1.xml · derivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,250

Underlying: Class A Common Stock · 98,250 shares

Expires 2031-04-27

F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc.,

F3 · price: a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), the option was received in the Mergers in exchange for a stock option to acquire 300,000 shares of Hyperfine common stock for $1.07.

F1 · derivative.exercise_date: The shares underlying this option vested as to 25% on June 30, 2022, with the remainder of the options vesting in equal monthly installments over the following three years, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001104659-21-153334 · tm2135698-18_4seq1.xml · nonDerivative · entry 1

Fattori Ruth A · CIK 0001306826 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891

F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which

F2 · price: Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 4,962 shares of Liminal Series A-2 preferred stock.

SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · derivative · entry 4

Huennekens R Scott · CIK 0001365493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,437

Underlying: Class A Common Stock · 237,437 shares

Expires 2031-04-27

F9 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share.

F8 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted).

SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · derivative · entry 3

Huennekens R Scott · CIK 0001365493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,437

Underlying: Class A Common Stock · 237,437 shares

Expires 2031-04-27

F7 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share.

F5 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a business combination that results in the operating business of Hyperfine and Liminal becoming a publicly traded company (a "SPAC transaction") within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $15.00 or more for at least 20 out of 30 consecutive trading days within three years of the closing of the SPAC transaction; (2) the completion of the initial public offering of Hyperfine and Liminal ("IPO")

F6 · derivative.exercise_date: within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 1.5 times $3.92 (as adjusted) within three years of the closing of the IPO; or (3) the closing of a private financing round within three years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 1.5 times $3.92 (as adjusted).

SEC source: 0001104659-21-153332 · tm2135698-15_4seq1.xml · derivative · entry 2

Huennekens R Scott · CIK 0001365493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 712,312

Underlying: Class A Common Stock · 712,312 shares

Expires 2031-04-27

F3 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"),

F4 · price: pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in connection with the Mergers in exchange for a stock option to acquire 2,175,000 shares of Hyperfine common stock for $1.07 per share.

F2 · derivative.exercise_date: The shares underlying this option vest as to 25% on June 30, 2022, with the remainder of the options vesting in equal monthly installments over the following 36 months, subject to Mr. Huennekens' continued service on each vesting date.

SEC source: 0001104659-21-153687 · tm2136411-1_4seq1.xml · derivative · entry 4

HC Sponsor LLC · CIK 0001833772 · 10% owner

HealthCor Group, LLC · CIK 0001409307 · 10% owner

Cohen Arthur Bruce · CIK 0001343780 · 10% owner

Healey Joseph Patrick · CIK 0001343779 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 4,920,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · kind: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · price: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · derivative.exercise_date: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · derivative.expiration_date: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F2 · ownership.direct: This Form 4 is being filed by HC Sponsor LLC (the "Sponsor"). HealthCor Group, LLC ("HealthCor Group") shares voting and/or dispositive control over the securities held by the Sponsor. HealthCor Group is controlled by Messrs. Arthur B. Cohen and Joseph P. Healey. Accordingly, all of the shares held by the Sponsor may be deemed to be beneficially held by HealthCor Group and Messrs. Cohen and Healey. Each such reporting person under this Form 4 disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interest therein and the filing of this Form 4 shall not be construed as an admission that any such reporting person is the beneficial owner of any securities covered by this Form 4.

SEC source: 0001104659-21-153687 · tm2136411-1_4seq1.xml · derivative · entry 3

HC Sponsor LLC · CIK 0001833772 · 10% owner

HealthCor Group, LLC · CIK 0001409307 · 10% owner

Cohen Arthur Bruce · CIK 0001343780 · 10% owner

Healey Joseph Patrick · CIK 0001343779 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 614,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · kind: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · price: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · derivative.exercise_date: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · derivative.expiration_date: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F2 · ownership.direct: This Form 4 is being filed by HC Sponsor LLC (the "Sponsor"). HealthCor Group, LLC ("HealthCor Group") shares voting and/or dispositive control over the securities held by the Sponsor. HealthCor Group is controlled by Messrs. Arthur B. Cohen and Joseph P. Healey. Accordingly, all of the shares held by the Sponsor may be deemed to be beneficially held by HealthCor Group and Messrs. Cohen and Healey. Each such reporting person under this Form 4 disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interest therein and the filing of this Form 4 shall not be construed as an admission that any such reporting person is the beneficial owner of any securities covered by this Form 4.

SEC source: 0001104659-21-153687 · tm2136411-1_4seq1.xml · nonDerivative · entry 2

HC Sponsor LLC · CIK 0001833772 · 10% owner

HealthCor Group, LLC · CIK 0001409307 · 10% owner

Cohen Arthur Bruce · CIK 0001343780 · 10% owner

Healey Joseph Patrick · CIK 0001343779 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,534,000

F3 · shares: The Reporting Persons have voting and dispositive power over the reported securities, which were acquired by affiliates of the Reporting Persons pursuant to a PIPE Investment in connection with the completion of the Business Combination.

F1 · price: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F2 · ownership.direct: This Form 4 is being filed by HC Sponsor LLC (the "Sponsor"). HealthCor Group, LLC ("HealthCor Group") shares voting and/or dispositive control over the securities held by the Sponsor. HealthCor Group is controlled by Messrs. Arthur B. Cohen and Joseph P. Healey. Accordingly, all of the shares held by the Sponsor may be deemed to be beneficially held by HealthCor Group and Messrs. Cohen and Healey. Each such reporting person under this Form 4 disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interest therein and the filing of this Form 4 shall not be construed as an admission that any such reporting person is the beneficial owner of any securities covered by this Form 4.

SEC source: 0001104659-21-153687 · tm2136411-1_4seq1.xml · nonDerivative · entry 1

HC Sponsor LLC · CIK 0001833772 · 10% owner

HealthCor Group, LLC · CIK 0001409307 · 10% owner

Cohen Arthur Bruce · CIK 0001343780 · 10% owner

Healey Joseph Patrick · CIK 0001343779 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,534,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F1 · price: In connection with the consummation of the transactions contemplated by the Business Combination Agreement, dated July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Hyperfine, Inc., Liminal Sciences, Inc. and the other parties thereto (the transactions contemplated thereby, the "Business Combination"), HealthCor domesticated as a Delaware corporation (the "Domestication") and changed its name to "Hyperfine, Inc." ("Hyperfine"). In connection with the Domestication, the reporting person's Class B ordinary shares, par value $0.0001 per share, of HealthCor, which were previously convertible into Class A ordinary shares of HealthCor, were automatically converted into shares of Class A common stock of Hyperfine, par value $0.0001 per share, on a one-for-one basis.

F2 · ownership.direct: This Form 4 is being filed by HC Sponsor LLC (the "Sponsor"). HealthCor Group, LLC ("HealthCor Group") shares voting and/or dispositive control over the securities held by the Sponsor. HealthCor Group is controlled by Messrs. Arthur B. Cohen and Joseph P. Healey. Accordingly, all of the shares held by the Sponsor may be deemed to be beneficially held by HealthCor Group and Messrs. Cohen and Healey. Each such reporting person under this Form 4 disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interest therein and the filing of this Form 4 shall not be construed as an admission that any such reporting person is the beneficial owner of any securities covered by this Form 4.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · derivative · entry 8

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 982,500

Underlying: Class A Common Stock · 982,500 shares

Expires 2031-04-14

F11 · price: Received in connection with the Mergers in exchange for a stock option to acquire 3,000,000 shares of Hyperfine common stock for $1.07 per share.

F10 · derivative.exercise_date: The shares underlying this option vested and became exercisable on December 15, 2021.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 7

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By 4C Holdings V, LLC

Disclosed balance after: 818,750

F9 · price: Received in connection with the Mergers in exchange for 2,500,000 shares of Hyperfine Series A preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 6

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By 4C Holdings I, LLC

Disclosed balance after: 14,236,538

F8 · price: Received in connection with the Mergers in exchange for 22,500,000 shares of Hyperfine Series B preferred stock and 38,239,355 shares of Liminal Series A-1 preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 5

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Bonnie E Gould Rothberg MD

Disclosed balance after: 95,507

F7 · price: Received in connection with the Mergers in exchange for 291,625 shares of Hyperfine Series B preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 4

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · 23rd Century Capital LLC

Disclosed balance after: 440,295

F6 · price: Received in connection with the Mergers in exchange for 1,344,413 shares of Hyperfine Series B preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 3

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · 2012 JMR Trust Common, LLC

Disclosed balance after: 585,737

F4 · price: Received in connection with the Mergers in exchange for 1,403,701 shares of Hyperfine Series B preferred stock and 701,700 shares of Liminal Series A-2 preferred stock.

F5 · ownership.nature: Dr. Rothberg is the sole manager of 4C Holdings I, LLC, 4C Holdings V, LLC and 2012 JMR Trust Common, LLC. Dr. Rothberg is the spouse of Bonnie E. Gould Rothberg MD and Dr. Rothberg's son is the manager of 23rd Century Capital LLC. Dr. Rothberg disclaims beneficial ownership of the shares held by his spouse and 23rd Century Capital LLC.

SEC source: 0001104659-22-002890 · tm222483-5_4aseq1.xml · nonDerivative · entry 1

ROTHBERG JONATHAN M · CIK 0001076352 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,074

F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc.,

F2 · price: a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 275,700 shares of Hyperfine Series B preferred stock and 76,739 shares of Liminal Series A-2 preferred stock.

SEC source: 0001104659-22-002888 · tm222483-3_4aseq1.xml · nonDerivative · entry 1

Fattori Ruth A · CIK 0001306826 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891

F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which

F2 · price: Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 4,962 shares of Liminal Series A-2 preferred stock.

SEC source: 0001104659-22-002889 · tm222483-4_4aseq1.xml · derivative · entry 4

Huennekens R Scott · CIK 0001365493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,437

Underlying: Class A Common Stock · 237,437 shares

Expires 2031-04-27

F9 · price: Received in connection with the Mergers in exchange for a stock option to acquire 725,000 shares of Hyperfine common stock for $1.07 per share.

F8 · derivative.exercise_date: The shares underlying this option vest and will become exercisable upon the first to occur of the following: (1) the completion of a SPAC transaction within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share of $30.00 or more for at least 20 out of 30 consecutive trading days within four years of the closing of the SPAC transaction; (2) the completion of an IPO within two years of Mr. Huennekens' start date and the Issuer's common stock achieving a closing price per share that equals or exceeds 3.0 times $3.92 (as adjusted) within four years of the closing of the IPO; or (3) the closing of a private financing round within four years of Mr. Huennekens' start date in which $50 million or more is raised and Hyperfine's stock price per share equals or exceeds 3.0 times $3.92 (as adjusted).